05:27:45 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2025-02-14 Bokslutskommuniké 2024
2024-11-14 Kvartalsrapport 2024-Q3
2024-08-16 Kvartalsrapport 2024-Q2
2024-05-30 Årsstämma 2024
2024-05-17 Kvartalsrapport 2024-Q1
2024-03-01 Ordinarie utdelning CSMED 0.00 DKK
2024-02-14 Bokslutskommuniké 2023
2023-12-15 Ordinarie utdelning CSMED 0.00 DKK
2023-07-18 Kvartalsrapport 2023-Q3
2023-05-17 Kvartalsrapport 2023-Q2
2023-04-14 Extra Bolagsstämma 2023
2023-02-17 Kvartalsrapport 2023-Q1
2023-02-14 Årsstämma 2023
2023-02-10 Ordinarie utdelning CSMED 0.00 DKK
2022-11-18 Bokslutskommuniké 2022
2022-08-13 Kvartalsrapport 2022-Q3
2022-05-20 Kvartalsrapport 2022-Q2
2022-02-18 Kvartalsrapport 2022-Q1
2021-12-10 Ordinarie utdelning CSMED 0.00 DKK
2021-12-09 Årsstämma 2022
2021-11-18 Bokslutskommuniké 2021

Beskrivning

LandDanmark
ListaSpotlight DK
SektorHälsovård
IndustriLäkemedel & Handel
CS Medica är ett danskt medicintekniskt bolag, dedikerat till läkemedelsforskning, utveckling, tillverkning och global kommersialisering. Bolaget blandar vetenskap och natur för att förbättra patienters liv med cannabinoidterapier för smärtlindring, och för att hantera autoimmuna och stressrelaterade symtom. Globalt erbjuder CS Medica CBD-behandlingar över disk (OTC), inklusive patenterade medicinska produkter, MHRA och MDR-registrerade artiklar, under varumärket CANNASEN® eller med egen märkning.
2022-12-16 15:57:13

CS MEDICA A/S ("CS MEDICA" or the" Company") announces that the company has signed a deal with Cleanpure Scandinavia AB & Cleanpure UK Ltd, who will distribute the entire CANNASEN[® ]portfolio on the Swedish market and the Amazon channels in the United Kingdom as Sweden. 

Lone Henriksen, CEO CS MEDICA, comments 
"We are happy to announce that CS MEDICA is enhancing its focus in the Swedish market with our new partnership. Cleanpure is based in Sweden with connections to all relevant stakeholders and already possesses a connection to a sales force, marketing, and logistic setup. The goal is to speed up brand awareness and sales in Sweden to the same level as the Danish market. Regarding Amazon, we want to optimize the Swedish presence and aim for the 2nd largest Amazon platform in Europe, the UK. Still, we especially want to benefit from our approval by MHRA (The Medicines and Healthcare products Regulatory Agency) to kick start the sales in the UK before year-end. Cleanpure is already familiar with the Amazon channel, and with a logistical solution, we see a perfect match".

Lone Henriksen, CEO CS MEDICA, continues
"We are additionally proud and glad to welcome Cleanpure, which is also one of our investors, who shows confidence in our products to become a strong partner in the business of being a distributor. This way of building a bridge on enhanced market focus, with already well-known stakeholders is something we value highly at CS MEDICA, and hopefully, it will not be the last of its kind".   

The partnership's primary focus is the speed-to-market of the CANNASEN[®] brand and products, which will be within reach in the UK before the end year, and in Sweden starting in 2023. 

Nils-Holger Olsson, Founder at Cleanpure, comments
"We see the CANNASEN[®] products as a great add-on to our current portfolio of innovative products within health and hygiene. We've been looking for products with unique technologies to expand our offerings to our customers. CS MEDICA has a competitive advantage in the market with its unique medical devices, cosmetic products, CBD technology, and proven efficacy. Cleanpure can benefit from this distinctive portfolio while growing the CANNASEN[®] brand with CS MEDICA."